iconEarnings Announcement After Market Close

Cyclacel Pharmaceuticals Inc CYCC:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 12:47 PM EDT
2.62quote price arrow up+0.08 (+3.15%)
Volume
115,652
52 week range
1.30 - 13.20
Loading...
  • Open2.22
  • Day High2.67
  • Day Low2.22
  • Prev Close2.54
  • 52 Week High13.20
  • 52 Week High Date07/19/23
  • 52 Week Low1.30
  • 52 Week Low Date04/29/24

Key Stats

  • Market Cap3.834M
  • Shares Out1.46M
  • 10 Day Average Volume4.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.56
  • YTD % Change-1.87

KEY STATS

  • Open2.22
  • Day High2.67
  • Day Low2.22
  • Prev Close2.54
  • 52 Week High13.20
  • 52 Week High Date07/19/23
  • 52 Week Low1.30
  • 52 Week Low Date04/29/24
  • Market Cap3.834M
  • Shares Out1.46M
  • 10 Day Average Volume4.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.56
  • YTD % Change-1.87

RATIOS/PROFITABILITY

  • EPS (TTM)-26.80
  • P/E (TTM)-0.10
  • Fwd P/E (NTM)-0.24
  • EBITDA (TTM)-25.422M
  • ROE (TTM)-216.30%
  • Revenue (TTM)419,999.987
  • Gross Margin (TTM)-
  • Net Margin (TTM)-5,370.24%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/14/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cyclacel Pharmaceuticals Inc

 

Profile

MORE
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies....
Christopher Henney Ph.D.
Independent Chairman of the Board
Spiro Rombotis
President, Chief Executive Officer, Director
Paul Mcbarron
Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
Address
200 Connell Dr Ste 1500
Berkeley Heights, NJ
07922-2811
United States

Top Peers

SYMBOLLASTCHG%CHG
FNCH
Finch Therapeutics Group Inc
1.90+0.02+1.06%
FWBI
First Wave BioPharma Inc
2.90-0.09-3.01%
APVO
Aptevo Therapeutics Inc
0.8121+0.0001+0.0123%
WINT
Windtree Therapeutics Inc
4.08+0.15+3.82%
ELOX
Eloxx Pharmaceuticals Inc
0.84-0.06-6.6667%